نتائج البحث - JanePreuss Hasselby

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Urokinase‐type plasminogen activator receptor (uPAR) on tumor‐associated macrophages is a marker of poor prognosis in colorectal cancer

    Urokinase‐type plasminogen activator receptor (uPAR) on tumor‐associated macrophages is a marker of poor prognosis in colorectal cancer حسب Martin Illemann, Ole Didrik Lærum, Jane Preuss Hasselby, Tine Thurison, Gunilla Høyer‐Hansen, Hans Jørgen Nielsen, Ib Jarle Christensen

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers

    Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers حسب Dan Calatayud, Christian Dehlendorff, Mogens K. Boisen, Jane Preuss Hasselby, Nicolai Aagaard Schultz, Jens Werner, Heike Immervoll, Anders Molven, Carsten Palnæs Hansen, Julia S. Johansen

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Initial experience with EUS-guided microbiopsy forceps in diagnosing pancreatic cystic lesions: A multicenter feasibility study (with video)

    Initial experience with EUS-guided microbiopsy forceps in diagnosing pancreatic cystic lesions: A multicenter feasibility study (with video) حسب Bojan Kovacevic, JohnGásdal Karstensen, RoaldFlesland Havre, Khanh Do-Cong Pham, Marc Giovannini, Emanuele Dabizzi, Paolo Giorgio Arcidiacono, Erwin Santo, EnriqueVazquez Sequeiros, Pia Klausen, CharlotteVestrup Rift, JanePreuss Hasselby, Anders Toxværd, Evangelos Kalaitzakis, Carsten Palnæs Hansen, Peter Vilmann

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

    Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) حسب Inna M. Chen, Julia S. Johansen, Susann Theile, Jessica Xin Hjaltelin, Sif I. Novitski, Søren Brunak, Jane Preuss Hasselby, Gro Linno Willemoe, Torben Lorentzen, Kasper Madsen, Benny Vittrup Jensen, Eva E. Wilken, Poul Geertsen, C.F. Behrens, Christian Nolsøe, Kirstine Lintrup Hermann, Inge Marie Svane, Dorte Nielsen

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: